Loading...
Memantine, an N-methyl D-aspartate (NMDA) receptor antagonist that modulates the neurotransmitter glutamate, is modestly effective for Alzheimer disease dementia. Preliminary studies have suggested that memantine may improve cognition in Lewy body spectrum dementias, including Parkinson disease dementia (PDD) and dementia with Lewy bodies (DLB). In addition, controversy persists regarding the relationship between DLB and PDD. The clinical and pathological features of these disorders overlap substantially. However, PDD and DLB may differ enough to warrant different treatment approaches. Researchers conducted a 24-week, multicenter, manufacturer-funded, randomized clinical trial of memantine (20 mg once daily) in patients with mild-to-moderat…